Victoria A. Jennings1*†Reah Rumbold-Hall1Gemma Migneco1Tyler Barr1Katrina Reilly1Nicola Ingram1Isabelle St Hilare2Samuel Heaton1Noura Alzamel1David Jackson3Christy Ralph3Susan Banerjee4Iain McNeish5John C. Bell2Alan A. Melcher6Carolina Ilkow2
Graham P. Cook1‡Fiona Errington-Mais1‡- 1Leeds Institute of Medical Research, School of Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom
- 2Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada
- 3Leeds Cancer Centre, St James’s Hospital, Leeds, United Kingdom
- 4The Royal Marsden Hospital, Fulham Road, London, United Kingdom
- 5Department of Cancer and Surgery, Imperial College London, London, United Kingdom
- 6The Institute of Cancer Research, Divisions of Radiotherapy and Imaging and Breast Cancer Research, Chester Beatty Laboratories, London, United Kingdom
A Corrigendum on
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment
By Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, St Hilare I, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP and Errington-Mais F (2024). Front. Immunol. 15:1500570. doi: 10.3389/fimmu.2024.1500570
In the published article, there was an error in the article title. Instead of “Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment”, it should be “Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment”.
In the published article, there was an error in the Funding statement. Several funders were omitted from the original statement. The correct Funding statement appears below.
“The authors declare that financial support was received for the research, authorship, and/or publication of this article. Ovarian Cancer Action funded Victoria Jennings, Reah Rumbold-Hall and the costs required to undertake this study. Alan Melcher was supported by CRUK (Programme grant CRM183X), Tyler Barr was supported by the Myrovlytis Trust and by an MRC/NIHR Cancer Research Transatlantic Development and Skills Enhancement Award (NIHR304246), Samuel Heaton by an MRC Discovery Medicine North (DiMeN) studentship (MR/N013840/1) and Noura Alzamel by a scholarship from Kuwait University. Nicola Ingram is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) (NIHR213331). Other authors were supported by their respective institutions. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care, or any other funders of this work.”
In the published article, there was an error in the Acknowledgements. Funders others than Ovarian Cancer Action were omitted from the original statement. The correct statement appears below.
“The authors would like to extend their sincere gratitude to Ovarian Cancer Action for their generous funding and support, which made this research possible. Their commitment to advancing ovarian cancer research, has been instrumental in enabling us to carry out this study. We thank the other organisations who supported the study and thank our colleagues Robert Salmond and Sandra Bell for the kind gift of materials and for their scientific input into this study.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: oncolytic virus, miRNA, tumour associated macrophage, tumour microenvironment, anti-tumour immunity
Citation: Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, Hilare IS, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow C, Cook GP and Errington-Mais F (2025) Corrigendum: Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment. Front. Immunol. 16:1601201. doi: 10.3389/fimmu.2025.1601201
Received: 27 March 2025; Accepted: 03 April 2025;
Published: 22 April 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Jennings, Rumbold-Hall, Migneco, Barr, Reilly, Ingram, Hilare, Heaton, Alzamel, Jackson, Ralph, Banerjee, McNeish, Bell, Melcher, Ilkow, Cook and Errington-Mais. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Victoria A. Jennings, dmlja2kuamVubmluZ3NAeW9yay5hYy51aw==
†Present address: Victoria A. Jennings, Jack Birch Unit for Molecular Carcinogenesis, Department of Biology & York Biomedical Research Institute, University of York, York, United Kingdom
‡These authors share last authorship